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Oral Presentations 23Hodgkin lymphoma (NHL). However, long-term outcomes of auto
HCT for HL and NHL have not been well described. We conducted
a retrospective cohort study to evaluate the probability and risk fac-
tors for long-term survival and late relapse in this population. Recip-
ients of auto HCT for HL (N5 407) and NHL (N5 960) between
1990 and 1998 reported to the CIBMTR and in continuous complete
remission (CR) for at least 2 years post-HCT were included in this
study . The median followup was 104 (range, 25–203) months for
HL and 107 (range, 25–198) months for NHL. NHL subtypes
were follicular (30%), diffuse large cell (45%), mantle cell (6%) and
other (7%). The median age of HL patients was 31 years compared
to 47 years for NHL; more HL patients were\20 years (15% vs
5%) while NHL patients were .50 years (6% vs 40%). Patients
were predominantly White (87%), male (60%), with chemosensitive
disease (82%),and KPS score$90 (67%). A greater proportion of HL
patients had history of B symptoms (52% vs 34%) and were $12
months from diagnosis (90% vs 59%) while use of total body irradi-
ation (TBI) was more prevalent for NHL (94% vs 64%). The prob-
ability of overall survival (OS) and cumulative incidence of relapse
and non-relapse mortality (NRM) at 10-years after HCT was 76%
(95% CI, 73–79%), 17% (13–22) and 13% (9–17%) for HL. The
10-year rates of OS, relapse and NRM for NHL were 77%
(72–82%), 26% (23–30%) and 11% (9–13%). On multivariate anal-
ysis, OS (Table) was significantly associated with histology, age at
HCT and time from diagnosis to HCT. Factors predictive for relapse
included histology (compared to HL, relative risk (RR) 1.5 (1.0–2.2)
for follicular, 1.4 (0.9–1.9) for diffuse large cell, 1.4 (0.8–2.8) for lym-
phoblastic/Burkitts, 4.6 (2.8–7.6) for mantle cell and 1.5 (0.9–2.4) for
other NHL), male gender (RR 1.3 (1.0–1.6)), use of TBI (RR 1.6 (1.2–
2.1)), use of growth factors (RR 1.5 (1.1–2.0)) and time since diagnosis
of $12 months (RR 1.9 (1.5–2.6)) while KPS score of $90 at HCT
decreased relapse risk (RR 0.8 (0.6–1.0)). Recipients of auto HCT
for HL and NHL who remain in remission for at least 2 years have
a very favorable subsequent long-term survival. However, they
remain at risk for late relapse and NRM. Mantle cell histology, older
age at HCT and increasing time between diagnosis and HCT are
predictive of adverse long-term survival.
Multivariate analysis for overall survival in patients surviving in
remission for at least 2 years after auto HCT
Variable N RR of death (95%CI) P-valueHistology
HL 399 1.00 \0.01
Follicular NHL 282 0.91 (0.63-1.32) 0.61
Diffuse large cell NHL 422 0.92 (0.64-1.31) 0.63
Lymphoblastic/Burkitts NHL 69 1.28 (0.66-2.48) 0.47
Mantle cell NHL 57 2.87 (1.70-4.87) \0.01
Other NHL 117 0.95 (0.58-1.57) 0.85
Age at HCT
\20 years 101 1.00 \0.01
20-49 years 843 0.94 (0.54-1.66) 0.84
$50 years 402 2.23 (1.24-4.00) \0.01
Time from diagnosis to HCT
\12 months 426 1.00
$12 months 920 2.23 (1.62-3.09) \0.01Other variables considered: gender, race, KPS score, CR status, stage, B
symptoms, chemosensitivity, pre-HCT radiation, pre-HCT chemother-
apy regimens, HCT year, TBI use, graft source, graft purging, growth
factor use and post-HCTradiation.55
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Adoptive transfer of tumor-specific cytotoxic T lymphocytes
(CTLs) can induces tumor regression in patients with several types
of lymphomas. Clinical responses appear to require the in vivo expan-sion and persistence of the infused CTLs so that IL-2 has frequently
been used to support CTL therapies. Although effective, IL-2 is
associated with significant toxicity and the expansion of regulatory
T cells (Treg). Thus alternative cytokines able to sustain the expan-
sion of CTLs but avoiding the toxic and negative effects of IL-2 are
highly demanded. IL-7 plays a crucial role in T-cell homeostasis, ap-
pears well tolerated, and does not influence Treg numbers or func-
tion. Unfortunately, IL-7 may fail to expand tumor-specific CTLs
in vivo because these cells lack IL-7Ra expression. To determine
whether forced expression of transgenic IL-7Ra improves CTL sur-
vival and expansion we used Epstein-Barr-Virus specific-CTLs
(EBV-CTLs) which we transduced with a retroviral vector encoding
IL-7Ra. After transduction, IL-7Ra was detectable on 58–76% of
EBV-CTLs. The transgenic IL-7Ra molecule was functional since
addition of IL-7 induced STAT5 phosphorylation only in EBV-
CTLs/IL-7Ra1. These EBV-CTLs/IL-7Ra1 and control CTLs
expanded equally in response to IL-2, but only EBV-CTL/IL-
7Ra1 significantly proliferated in the presence of IL-7 (5 ng/mL)
[from 1  106 to 1.03  108 cells/ml (range, 0.38–2.9  108)] over
five weeks of culture. As anticipated, the EBV-CTL/IL-7Ra1 subset
of cells were selected on exposure to IL-7 and so formed an increasing
proportion of the total T cell population. Importantly, IL-7 expanded
EBV-CTLs/IL7Ra1 retained their ability to respond to other com-
mon-g-chain cytokines such as IL-2 and IL-15, and did not modify
their antigen specificity measured by tetramer staining and by
IFNg release. These CTLs also remained polyclonal, retaining
both their effector-memory profile and MHC-restricted killing of au-
tologous LCLs. Antigen or cytokine withdrawal abrogated CTL ex-
pansion. These in vitro characteristics were replicated in a xenograft
mouse model, in which EBV-CTLs/IL7Ra1 expanded in response
to IL-2 or IL-7 and maintained their antitumor effects. In conclusion,
we have developed a novel approach to safely expand adoptively trans-
ferred CTLs using IL-7. This approach can be beneficial for CTL
therapies in patients with lymphomas and other malignancies.PEDIATRIC DISORDERS
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A PILOT STUDY OF REDUCED INTENSITY CONDITIONING (RI) WITH
BUSULFAN (BU), FLUDARABINE (FLU), AND ALEMTUZUMAB FOLLOWED
BY ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) TO INDUCE
SUSTAINED MIXED DONOR CHIMERISM IN PATIENTS WITH SYMPTOM-
ATIC SICKLE CELL DISEASE (SCD)
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SCD can be cured by HLA matched family donor AlloSCT (Wal-
ters et al, NEJM, 1996). Patients undergoing myeloablative Al-
loSCT are at risk for many complications post SCT including
death, graft versus host disease (GVHD), and life threatening infec-
tions, thus making RIC regimens an attractive alternative. Having an
unaffected, HLA-matched identical sibling is another major obstacle
for most SCD patients to proceed to AlloSCT(Bhatia et al, BMT,
2008). Umbilical cord blood (UCB) has been proven to be an excel-
lent alternate donor source that can safely reconstitute hematopoie-
sis after AlloSCT(Cairo et al, BBMT, 2008). In this study, we report
the results of RIC and AlloSCT from matched family and UCB do-
nors in 14 patients (12M:2F) with symptomatic SCD (HbSS 5 8,
HbSC 5 3, HbSßThal 5 3). Conditioning was Bu (4mg/kg  4d
# 4 yrs and 12.8mg/ kg  4d . 4 yrs), Flu (30mg/m2  6d), and
Alemtuzumab (2mg/m2  1d, 6mg/m2  2d, and 20mg/m2  2d).
Median age was 6.15 yrs (1.5–16). Donor sources: 6-6/6 HLA-
matched sibling bone marrow (BM), 2-6/6 sibling UCB, 3-4/6
and 3-5/6 unrelated UCB. Bone marrow recipients received median
cell doses of 5.463.5  108 TNC/kg and 4.9861.8  106 CD34/kg
while cord blood recipients received median cell doses of 4.162.0 
107 TNC/kg and 2.261.8  105 CD34/kg. All received tacrolimus
and mycophenolate mofetil as GVHD prophylaxis and phenytoin
or keppra as seizure prophylaxis for 180 days post SCT. Median neu-
trophil and platelet recovery was day 27(0–47) and day 43(0–86), re-
spectively. One patient had primary graft failure at day 160 post
